Outcomes of adjuvant epithelial growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) treatment for EGFR-mutant non-small-cell lung cancer: a propensity-score analysis

Small molecule tyrosine kinase inhibitors (TKIs) have transformed the management of advanced non-small-cell lung cancer (NSCLC) harboring activating epithelial growth factor receptor (EGFR) mutations, while the efficacy of TKIs in the adjuvant setting remains unclear. We collected the data of 209 EG...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Shufen, Ma, Ge, Guo, Jing, Ding, Aiping, Wang, Shasha, Yu, Guohong, Chen, Lei, Yuan, Yonggang, Xiao, Wenjing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5599620/
https://www.ncbi.nlm.nih.gov/pubmed/28912511
http://dx.doi.org/10.1038/s41598-017-11725-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5599620/
https://www.ncbi.nlm.nih.gov/pubmed/28912511
http://dx.doi.org/10.1038/s41598-017-11725-9

Ejemplares similares